Our History

The underlying technology platform at Veloxis was developed to address a critical roadblock experienced by pharmaceutical companies related to poor oral absorption (bioavailability) of otherwise high-potential drugs.

Faced with the problems of new drug substances with low water solubility, H. Lundbeck A/S decided to put forth a focused effort into the development and implementation of dissolution- and absorption-enhancing methods. The groundbreaking work resulted in the development of a unique technology that improves the bioavailability of low water-soluble or -insoluble drug substances so that these drugs can be taken orally.

To capitalize on its potential, H. Lundbeck A/S decided to spin out this technology into LifeCycle Pharma A/S.

In June 2002, LifeCycle Pharma A/S was formed as a spin-off of H. Lundbeck A/S.

In July 2011, LifeCycle Pharma became Veloxis Pharmaceuticals A/S.